Research Article - Biomedical Research (2018) Volume 29, Issue 3
Comprehensive analysis clinical effectiveness of Tirofiban for patients with non-ST-elevation acute coronary syndrome
Background: To systematically assess the effectiveness and safety of tirofiban in patients with non-STelevation acute coronary syndromes (NSTE-ACS).
Methods: We search the online databases in both English and Chinese from inception to 2017 to collect randomized controlled trials about tirofiban for NSTE-ACS patients in early medicine conservative treatment. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality of included studies.
Results: A total of 10 randomized controlled trials were enrolled involving 6405 patients. The results of meta-analysis showed that: (1) The incidences of cardiovascular events of composite endpoints in the trial group were lower than that in the control group (during One week: relative risk (RR)=0.55, 95% confidence interval (95%CI: 0.40, 0.74, P<0.001) and the incidences of cardiovascular events of composite endpoints in the trial group were lower than that in the control group (during 30 days: RR=0.45, 95%CI0.40, 0.75, P<0.001). (2) The incidence of bleeding in the trial group was higher than that in the control group (RR=1.31, 95%CI: 1.00-1.72).
Conclusions: Compared with routine treatment alone, tirofiban has better therapeutic effects in early conservative treatment for patients with non-ST-elevation acute coronary syndromes, but the incidence of bleeding is relatively high.Author(s): Jianfei Zheng, Xudong Xiang, Huixia Li, Bing Xiao, Ting Yuan, Xun Gong, Shuo Yao